BTMD Stock Forecast 2025-2026
Distance to BTMD Price Targets
BTMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Biote (BTMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BTMD and similar high-potential opportunities.
Latest BTMD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, BTMD has a bullish consensus with a median price target of $7.50 (ranging from $6.00 to $9.00). Currently trading at $3.30, the median forecast implies a 127.3% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from George Kelly at Roth MKM, projecting a 172.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTMD Analyst Ratings
BTMD Price Target Range
Latest BTMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Craig-Hallum | Alex Fuhrman | Buy | Maintains | $8.00 |
| Dec 16, 2024 | Craig-Hallum | Alex Fuhrman | Buy | Initiates | $12.00 |
| Mar 13, 2024 | Roth MKM | George Kelly | Buy | Reiterates | $9.00 |
| Feb 20, 2024 | B. Riley Securities | Jeff Van Sinderen | Buy | Initiates | $9.00 |
| Feb 1, 2024 | Jefferies | Kaumil Gajrawala | Buy | Initiates | $6.55 |
| Jan 18, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $9.00 |
| Jan 18, 2024 | Roth MKM | George Kelly | Buy | Maintains | $7.00 |
| Aug 15, 2023 | TD Cowen | Brian Holland | Outperform | Maintains | $7.00 |
| Aug 14, 2023 | Roth MKM | George Kelly | Buy | Reiterates | $12.00 |
| Mar 30, 2023 | Roth MKM | George Kelly | Buy | Maintains | $11.00 |
| Sep 27, 2022 | Truist Securities | Gregory Fraser | Buy | Initiates | $10.00 |
| Jun 24, 2022 | Cowen & Co. | Brian Holland | Outperform | Initiates | $11.00 |
| Jun 23, 2022 | Roth Capital | George Kelly | Buy | Initiates | $9.00 |
Biote Corp. (BTMD) Competitors
The following stocks are similar to Biote based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biote Corp. (BTMD) Financial Data
Biote Corp. has a market capitalization of $175.31M with a P/E ratio of 36.7x. The company generates $197.19M in trailing twelve-month revenue with a 1.6% profit margin.
Revenue growth is +9.0% quarter-over-quarter, while maintaining an operating margin of +10.5% and return on equity of -3.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biote Corp. (BTMD) Business Model
About Biote Corp.
Provides hormone replacement therapy solutions.
Biote Corp. generates revenue through its bioidentical hormone replacement therapy services, primarily utilizing innovative pellet therapy for hormone optimization. The company also educates healthcare providers to effectively implement its therapies, enhancing their market adoption and driving sales.
With a focus on personalized health solutions, Biote Corp. is positioned within the growing sectors of wellness, anti-aging, and preventive medicine, aligning with trends towards personalized medicine. The company is part of the expanding biotechnology and healthcare market, with potential for growth driven by increasing demand for its innovative health solutions.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
217
CEO
Mr. Bret Christensen
Country
United States
IPO Year
2022
Website
www.biote.comBiote Corp. (BTMD) Latest News & Analysis
Biote Corp. (NASDAQ: BTMD) announced that its Board members and CEO Bret Christensen purchased about 260,000 shares of the company's stock in open market transactions.
Board members and the CEO buying shares signals strong confidence in Biote's future, potentially boosting investor sentiment and indicating alignment with shareholder interests.
Biote Corp. (NASDAQ:BTMD) will hold its Q4 2024 Earnings Conference Call on March 12, 2025, at 5:00 PM ET, featuring corporate leaders and analysts from various firms.
The earnings call provides insights into Biote Corp.'s financial performance and strategic direction, which can influence stock price and investor sentiment.
Biote (NASDAQ: BTMD) reported Q4 2024 revenue of $49.8M, with procedure revenue at $36.6M and a gross profit margin of 71.8%.
Biote's strong Q4 revenue and high gross profit margin indicate robust demand and operational efficiency, potentially enhancing investor confidence and stock performance.
Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call
1 month agoBiote Corp. (Nasdaq: BTMD) will announce its Q4 and full year financial results on March 12, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Biote's upcoming financial results announcement could indicate its growth trajectory and performance, impacting stock valuation and investor sentiment in the preventive health sector.
Biote Announces CEO Retirement and Succession Plan
2 months agoBiote Corp. (NASDAQ: BTMD) announced CEO Terry Weber will retire on February 1, 2025, transitioning to a Strategic Advisor role. Bret Chr. has been appointed as her successor.
Leadership changes can signal strategic shifts and impact company performance, influencing investor confidence and stock prices. Monitoring the transition is crucial for assessing future growth potential.
Biote Corp. (BTMD) and Doximity (DOCS) have shown performance metrics in 2023, relative to their sector, but specific figures are not provided in the excerpt.
Performance comparisons highlight how BTMD and DOCS are faring relative to their peers, influencing investor sentiment and potential investment decisions in the biotech and tech sectors.
Frequently Asked Questions About BTMD Stock
What is Biote Corp.'s (BTMD) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Biote Corp. (BTMD) has a median price target of $7.50. The highest price target is $9.00 and the lowest is $6.00.
Is BTMD stock a good investment in 2025?
According to current analyst ratings, BTMD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTMD stock?
Wall Street analysts predict BTMD stock could reach $7.50 in the next 12 months. This represents a 127.3% increase from the current price of $3.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biote Corp.'s business model?
Biote Corp. generates revenue through its bioidentical hormone replacement therapy services, primarily utilizing innovative pellet therapy for hormone optimization. The company also educates healthcare providers to effectively implement its therapies, enhancing their market adoption and driving sales.
What is the highest forecasted price for BTMD Biote Corp.?
The highest price target for BTMD is $9.00 from George Kelly at Roth MKM, which represents a 172.7% increase from the current price of $3.30.
What is the lowest forecasted price for BTMD Biote Corp.?
The lowest price target for BTMD is $6.00 from at , which represents a 81.8% increase from the current price of $3.30.
What is the overall BTMD consensus from analysts for Biote Corp.?
The overall analyst consensus for BTMD is bullish. Out of 6 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are BTMD stock price projections?
Stock price projections, including those for Biote Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.